Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares | ||
By: Nasdaq / GlobeNewswire - 17 Oct 2018 | Back to overview list |
|
FIT Biotech Oy Company release October 17, 2018 at 06:15 PM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on December 22, 2017 between the FIT Biotech Oy ("Company") and Alpha Blue Ocean ("ABO") the Company's Board of Directors have resolved on October 17, 2018 to approve ABO's request relating to the funding programme to convert EUR 120,000 worth of Convertible Capital Notes into the Company's K shares. Due to the conversion of the Convertible Capital Notes, the Company transfers 300,000,000 new K shares in the Company to ABO with the conversion price of EUR 0.0004 per share and the share capital of the Company will be increased by EUR 120,000.00. The Board authorization is based on General Meeting April 12, 2018. The Company holds 1,001,924,221 K shares. The K shares will be admitted to trading on First North Finland on or about October 22, 2018. After this transaction FIT Biotech Oy has listed shares amounting to 3,082,307,467 K shares. FIT BIOTECH OY Board of Directors For further information: Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000 About FIT Biotech FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines. FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy. DISTRIBUTION: |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |